Advocacy intelligence hub — real-time data for patient organizations
University Hospital Regensburg
University of California, San Francisco — PHASE2
Hackensack Meridian Health
VITRAKVI: FDA approved
VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
VITRAKVI
Bayer HealthCare Pharmaceuticals Inc.
VITRAKVI
(larotrectinib)Orphan drugBayer HealthCare Pharmaceuticals Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified e...
Browse all Embryonal tumor with multilayered rosettes news →
Nancy D. Perrier, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Ralph Salloum, M.D
Pediatric Brain Tumor Consortium
📍 BOSTON, MA
Helen E Heslop, MD, MD
Baylor College of Medicine
📍 HOUSTON, TX
Sarah E Leary, M.D
Children's Oncology Group
📍 SEATTLE, WA
Brian Kushner, MD, MD
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Stanislaw R. Burzynski, MD, PhD, M.D., Ph.D
Burzynski Research Institute
📍 HOUSTON, TX
View all Embryonal tumor with multilayered rosettes specialists →